Conference Coverage

Art therapy linked to slowed Parkinson’s progression


 

FROM ECNP 2021

Many benefits, no side effects

Rebecca Gilbert, MD, PhD, vice president and chief scientific officer of the American Parkinson Disease Association, who was not involved in either study, told this news organization that the idea of art therapy for patients with Parkinson’s is “very reasonable.”

She highlighted that “people with Parkinson’s have many issues with their visuospatial abilities,” as well as their depth and distance perception, and so “enhancing that aspect could potentially be very beneficial.”

“So I’m hopeful that it’s a really good avenue to explore, and the preliminary data are very exciting.”

Dr. Gilbert also highlighted that the “wonderful” aspect of art therapy is that there are “so many benefits and not really any side effects.” Patients can “take the meds … and then enhance that with various therapies, and this would be an additional option.”

Another notable aspect of art therapy is the “social element” and the sense of “camaraderie,” although that has “to be teased out from the benefits you would get from the actual art therapy.”

Finally, Dr. Gilbert pointed out that the difference between the current trial and Dr. Cucca’s trial is the presence of a control group.

“Of course, it’s not blinded, because you know whether you got therapy or not … but that extra element of being able to compare with a group that didn’t get the treatment gives it a little more weight in terms of the field.”

No funding was declared. The authors have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Pimavanserin reduced dementia-related psychotic symptoms without affecting cognition
Federal Practitioner
CBT by phone reduces depression in Parkinson’s disease
Federal Practitioner
Concussion linked to risk for dementia, Parkinson’s disease, and ADHD
Federal Practitioner
Sublingual apomorphine alleviates off episodes in Parkinson’s disease
Federal Practitioner
Concussion linked to risk for dementia, Parkinson’s disease, and ADHD
Federal Practitioner
Prostate drugs tied to lower risk for Parkinson’s disease
Federal Practitioner
Neurologic disorders ubiquitous and rising in the U.S.
Federal Practitioner
Neurologic drug prices jump 50% in five years
Federal Practitioner
Fall prevention advice for patients with Parkinson’s
Federal Practitioner
Anxiety, inactivity linked to cognitive impairment in Parkinson’s
Federal Practitioner